Application of chiral-specificity of amino acids on the novel development of antipsychotic drugs for schizophrenia

2017 Fiscal Year Final Research Report

• Project/Area Number: 26461713
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Psychiatric science
• Research Institution: Tokyo Metropolitan Tama Medical Center (Department of Clinical Research) (2016-2017); Tokyo Medical and Dental University (2014-2015)
• Principal Investigator: YAMAMOTO Naoki 東京都立多摩総合医療センター(臨床研究・教育研修センター(臨床研究部)), 精神神経科, 部長 (70312296)
• Project Period (FY): 2014-04-01 – 2018-03-31
• Keywords: D－セリン / NMDA受容体 / 統合失調症

Outline of Final Research Achievements

In this study I have focused on chiral-specificity of amino acids to understand molecular basis in developing novel antipsychotic drugs for schizophrenia. D-Serine, an NMDA receptor coagonist, plays a crucial role in neurocognitive functions. From a pathophysiological aspect, dysfunction of D-serine/NMDA receptor signaling system may be involved in schizophrenia-related symptoms. To obtain further insights into the molecular basis of schizophrenia and other related mental disorders, I have investigated the genetic association of candidate genes and schizophrenia as case-control study. I obtained profiles of the relationship of these genes, including the splicing system of them, and schizophrenia.

Free Research Field

精神医学